Disruption of immune cells in blood is linked to cancer outcomes, new tool reveals
The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...